Content block block-961845479-1776820492
Body
| Description | Click icon to view file |
|---|---|
| An Official ATS Statement: Hepatotoxicity of Antituberculosis Therapy American Thoracic Society |
 |
| California TB Risk Assessments |  |
| Confidential Morbidity Report – Tuberculosis County of Orange, Health Care Agency, Public Health Services |
|
| Diagnosis of Tuberculosis in Adults and Children, 2017 Guidelines American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America |
|
| Diagnostic Standards and Classification of Tuberculosis in Adults and Children American Thoracic Society |
|
| Drug-Resistant Tuberculosis: A Survival Guide for Clinicians, 3rd Edition Curry International Tuberculosis Center |
|
| Interferon Gamma Release Assays (IGRA's) Centers for Disease Control & Prevention |
|
| Latent Tuberculosis Infection: A Guide for Primary Healthcare Providers Centers for Disease Control & Prevention |
|
| Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis Centers for Disease Control & Prevention |
|
| Sample LTBI Treatment Record Book | |
| Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection Centers for Disease Control & Prevention, MMWR; vol. 49/No. RR-6 |
|
| Three Months Once Weekly Isoniazid Plus Rifapentine (3HP) Trifold Pamphlet | |
| Treatment of Tuberculosis American Thoracic Society |
|
| Treatment of Drug-Susceptible Tuberculosis, 2016 Guidelines American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America |
|